Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Strange Alexander Ramsay
 2. Date of Event Requiring Statement (Month/Day/Year)
01/26/2015		 3. Issuer Name and Ticker or Trading Symbol
Zosano Pharma Corp [ZSAN]
(Last)
(First)
(Middle)
C/O ZOSANO PHARMA CORPORATION, 34970 ARDENTECH COURT		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP, Strategy & Corp. Develop.
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

FREMONT, CA 94555		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   (1) 07/25/2022 Common Stock 6,528 $ 1.4 D  
Employee Stock Option (right to buy)   (2) 12/11/2022 Common Stock 12,278 $ 1.4 D  
Employee Stock Option (right to buy)   (3) 02/15/2023 Common Stock 6,193 $ 1.4 D  
Employee Stock Option (right to buy)   (4) 07/12/2023 Common Stock 2,500 $ 1.4 D  
Employee Stock Option (right to buy)   (5) 04/15/2024 Common Stock 3,750 $ 1.28 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Strange Alexander Ramsay
C/O ZOSANO PHARMA CORPORATION
34970 ARDENTECH COURT
FREMONT, CA 94555		       VP, Strategy & Corp. Develop.  

Signatures

/s/ Robert W. Sweet, Jr., Attorney-in-Fact for Alexander R. Strange 01/26/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option became exercisable as to 1,632 shares on July 25, 2013 and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years.
(2) The option became exercisable as to 3,069 shares on December 11, 2013 and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years.
(3) The option became exercisable as to 1,548 shares on February 15, 2014 and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years.
(4) The option became exercisable as to 625 shares on July 12, 2014 and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years.
(5) 25% of the total shares shall vest on April 15, 2015 and the remainder of the total shares shall vest in equal monthly installments over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.